tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NeuroScientific Biopharmaceuticals Reports Promising Results for StemSmart MSC in Renal Transplantation

Story Highlights
  • NeuroScientific Biopharmaceuticals focuses on therapies for immune-inflammatory disorders.
  • StemSmart MSC therapy shows promise in preventing and treating renal graft failure.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NeuroScientific Biopharmaceuticals Reports Promising Results for StemSmart MSC in Renal Transplantation

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) is now available.

NeuroScientific Biopharmaceuticals Ltd announced promising results from early studies of their StemSmart MSC therapy in renal transplantation. The therapy showed potential in preventing and treating graft failure and rejection, with positive outcomes in patients facing acute renal rejection. The studies demonstrated the therapy’s safety and tolerability, suggesting it could mitigate kidney damage associated with transplantation, representing a significant advancement for deceased-donor renal transplants.

More about Neuroscientific Biopharmaceuticals Ltd.

NeuroScientific Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing therapies for immune-inflammatory disorders. Their primary product, StemSmart MSC, is aimed at addressing conditions such as Crohn’s Disease, kidney transplants, lung disorders, and GvHD, with a significant market focus on organ transplant immuno-suppressants.

Average Trading Volume: 615,863

Technical Sentiment Signal: Buy

Current Market Cap: A$61.53M

See more data about NSB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1